Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $269,317.80 in Stock

Posted by Defense World Staff on Apr 27th, 2026

Adaptive Biotechnologies Corporation (NASDAQ:ADPT – Get Free Report) COO Julie Rubinstein sold 19,060 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $14.13, for a total transaction of $269,317.80. Following the completion of the transaction, the chief operating officer directly owned 390,808 shares of the company’s stock, valued at $5,522,117.04. This trade represents a 4.65% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

On Friday, April 24th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.02, for a total transaction of $267,221.20.
On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.66, for a total transaction of $453,595.06.
On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.55, for a total transaction of $277,323.00.
On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.18, for a total transaction of $270,270.80.
On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.15, for a total transaction of $250,639.00.
On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $12.77, for a total transaction of $243,396.20.
On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.56, for a total transaction of $258,453.60.
On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.83, for a total transaction of $458,855.03.
On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $14.45, for a total transaction of $275,417.00.
On Monday, March 23rd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $13.83, for a total transaction of $263,599.80.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $14.14 on Monday. The firm has a market capitalization of $2.18 billion, a PE ratio of -35.35 and a beta of 2.29. The firm has a 50-day moving average price of $14.50 and a 200 day moving average price of $15.99. Adaptive Biotechnologies Corporation has a 12-month low of $7.16 and a 12-month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The company had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The company’s revenue was up 51.0% on a year-over-year basis. During the same quarter last year, the business posted ($0.23) earnings per share. On average, research analysts expect that Adaptive Biotechnologies Corporation will post -0.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Friday, February 6th. JPMorgan Chase & Co. raised their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Adaptive Biotechnologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Read Our Latest Research Report on ADPT

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds and other institutional investors have recently modified their holdings of ADPT. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $28,000. Sound Income Strategies LLC acquired a new stake in shares of Adaptive Biotechnologies in the third quarter valued at approximately $30,000. EverSource Wealth Advisors LLC increased its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. increased its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at approximately $51,000. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

(Get Free Report)

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.